European positive opinion for Latuda in schizophrenia
This article was originally published in Scrip
Executive Summary
Latuda (lurasidone) has been given a positive recommendation by the committee that advises on drug approvals in Europe. The product, which originated from Dainippon Sumitomo Pharma (DSP) and is partnered with Takeda in Europe, should be granted marketing authorization for the treatment of adults aged 18 and over with schizophrenia, said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).